Impax Asset Management Group plc Has $16.17 Million Stake in Johnson & Johnson $JNJ

Impax Asset Management Group plc increased its position in Johnson & Johnson (NYSE:JNJ) by 62.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 105,863 shares of the company’s stock after purchasing an additional 40,845 shares during the quarter. Impax Asset Management Group plc’s holdings in Johnson & Johnson were worth $16,171,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in JNJ. Police & Firemen s Retirement System of New Jersey boosted its position in shares of Johnson & Johnson by 4.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 365,252 shares of the company’s stock valued at $55,792,000 after acquiring an additional 14,099 shares in the last quarter. Bailard Inc. boosted its holdings in Johnson & Johnson by 9.2% during the second quarter. Bailard Inc. now owns 154,306 shares of the company’s stock valued at $23,570,000 after purchasing an additional 13,012 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Johnson & Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after purchasing an additional 1,225,676 shares during the period. Maple Capital Management Inc. grew its stake in shares of Johnson & Johnson by 2.3% in the 2nd quarter. Maple Capital Management Inc. now owns 171,848 shares of the company’s stock valued at $26,250,000 after purchasing an additional 3,867 shares during the period. Finally, ABC Arbitrage SA acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $2,259,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $195.19 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $196.00. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm’s 50 day moving average is $185.46 and its 200-day moving average is $169.66. The firm has a market capitalization of $470.27 billion, a price-to-earnings ratio of 18.84, a PEG ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on JNJ. Sanford C. Bernstein boosted their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Cowen restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Bank of America lifted their price target on shares of Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a report on Wednesday, October 15th. Finally, Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $200.52.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.